Sensory insole system for diabetic patients achieves reduction in recurrent ulcers

A VA Angels Diversified Fund 1 Portfolio Company

Improvements that enable better miniaturisation of technology leads to higher-quality wearable health solutions, including digital devices that were “never before possible’, said Breanne Everett (Orpyx Medical Technologies, Calgary, Canada) at the American College of Wound Healing and Tissue Repair (ACWHTR; 11-12 October 2019, Chicago, USA).

Furthermore, new directions in reimbursement toward remote physiologic monitoring are enabling alignment of patient, provider and payer incentives, she revealed. “With the right tools, providers can now be paid to deliver sustained, prevention-based wound management.” Everett, a medical doctor and resident in plastic and reconstructive surgery at the University of Calgary, was delivering a presentation entitled, “Foot pressure dynamic management: changing the game,” in which she outlined the diabetes epidemic among North Americans and its impact on diabetic peripheral neuropathy.

In her talk, Everett drew attention to the findings of a study on a sensory insole system developed by Orpyx—called SurroSense Rx—where she is CEO and president. Researchers had sought to determine the device’s efficacy in reducing foot ulcer recurrence in high-risk patients, hypothesising that such a system would be effective in achieving a decrease. The trial, “Innovative intelligent insole system reduces diabetic foot ulcer recurrence at plantar sites: a prospective, randomized, proof-of-concept study”, was carried out by Caroline Abbott et al and published in the October issue of The Lancet Digital Health.


Leave a Comment